Efficacy and Safety of Grazax in Children

Summary

The purpose of this study is to investigate if immunotherapy with Grazax is safe and reduces the hayfever symptoms and the use of symptom relieving medications in children during the grass pollen season

Timeline

Start

2006-11

Primary completion

2007-09

Completion

2007-11

Outcome

Met primary endpoint

paper The rhinoconjunctivitis symptom and medication scores and the asthma symptom score were all statistically significantly different between the 2 treatment groups. PMID 19130937 ↗

paper The differences in medians relative to placebo were 24%, 34%, and 64% in favor of active treatment. PMID 19130937 ↗

Publications

• Results Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7. doi: 10.1016/j.jaci.2008.10.044.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GRAZAX-R	Unknown	75000 unknown	Other

Indications